Key Highlights
- Dr. Joseph E. Bavaria, renowned cardiac surgeon, joins PECA Labs board.
- Bavaria brings over 30 years of cardiac and thoracic surgery experience.
- PECA Labs advances cardiovascular implants with novel polymeric materials.
- MASA Valve: Durable, non-biologic valve to reduce repeat surgeries.
- exGraft: First FDA-cleared polymeric vascular graft by PECA Labs.
Source: Business Wire
Notable Quotes
- “PECA Labs is working to solve some important challenges in cardiovascular implants, including the use of next-generation polymeric materials, which could make significant improvements to patient outcomes.” — Dr. Joseph E. Bavaria, Chair of Cardiac Surgery at Jefferson Health
- “Dr. Bavaria’s extensive leadership in cardiovascular surgery, particularly in innovating valve repair and replacement, will be immeasurable as we continue to develop and commercialize our MASA Valve and our STEALTH valve technologies.” — Doug Bernstein, CEO at PECA Labs
SoHC's Take
The addition of Dr. Joseph E. Bavaria to PECA Labs’ board signifies a substantial enhancement in the company’s leadership. Dr. Bavaria’s unparalleled expertise and extensive background in cardiac and thoracic surgery, along with his profound research and leadership roles, will be instrumental as PECA Labs pushes the envelope in developing cutting-edge cardiovascular implants. PECA Labs’ commitment to pioneering non-biologic polymeric valves, such as the MASA Valve, and expanding capabilities of grafts like exGraft, underscores their strategic focus on improving patient outcomes by reducing the need for repeated interventions. The future looks promising for PECA Labs as they continue to innovate and potentially revolutionize the cardiovascular implant industry.
